Rituximab in the management of refractory myasthenia gravis

Muscle and Nerve

Volumn 41, Issue 3, 2010, Pages 375-378

  Zebardast, Nazlee ^a   Patwa, Huned S ^a   Novella, Steven P ^a   Goldstein, Jonathan M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppression; Myasthenia gravis; Refractory; Rituximab; Treatment

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MUSCLE ANTIBODY; MUSCLE SPECIFIC KINASE ANTIBODY; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIPLOPIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHOLINESTERASE INHIBITORS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISONE; PYRIDOSTIGMINE BROMIDE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77649159695     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21521     Document Type: Article

References (17)

1. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4:317-327.
2. Dalakas MC. Inhibition of B cell functions: implications for neurology. Neurology 2008;70:2252-2260.
3. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14: 520-535.
4. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004;77:196-197.
5. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007;78:77.
6. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006;33:575-580.
7. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007;254:968-969.
8. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-250.
9. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201-202.
10. Shiratori S, Kondo T, Kubota K, Wakasa K, Ibata M, Shono Y, et al. Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma. Rinsho Ketsueki 2008;49:1536-1540.
11. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-293.
12. RXList. http://www.rxlist.com/rituxan-drug.htm#
13. Tandan R, Potter C, Bradshaw DY. Pilot trial of rituximab in myasthenia gravis. Neurology 2008;70(suppl 1):A301.
14. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, et al. Rituximab in refractory myasthenia gravis: a follow-up study of patients with anti-AChR or anti-MuSK antibodies. Neurology 2008; 70(suppl 1):A301.
15. FDA public health advisory. Life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. http://www.fda.gov/Cder/Drug/advisory/rituximab.htm, Dec 18, 2008.
16. Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 2006;12:293-298.
17. McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 2009;146: 233-246.